GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Durect Corp (NAS:DRRX) » Definitions » PB Ratio

Durect (Durect) PB Ratio

: 1.87 (As of Today)
View and export this data going back to 2000. Start your Free Trial

The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. As of today (2024-04-18), Durect's share price is $0.91. Durect's Book Value per Share for the quarter that ended in Dec. 2023 was $0.49. Hence, Durect's PB Ratio of today is 1.87.

The historical rank and industry rank for Durect's PB Ratio or its related term are showing as below:

DRRX' s PB Ratio Range Over the Past 10 Years
Min: 1.03   Med: 7.54   Max: 66.81
Current: 1.86

During the past 13 years, Durect's highest PB Ratio was 66.81. The lowest was 1.03. And the median was 7.54.

DRRX's PB Ratio is ranked better than
53.48% of 963 companies
in the Drug Manufacturers industry
Industry Median: 1.9 vs DRRX: 1.86

During the past 12 months, Durect's average Book Value Per Share Growth Rate was -55.60% per year. During the past 3 years, the average Book Value Per Share Growth Rate was -37.20% per year. During the past 5 years, the average Book Value Per Share Growth Rate was -12.30% per year. During the past 10 years, the average Book Value Per Share Growth Rate was -5.20% per year.

During the past 13 years, the highest 3-Year average Book Value Per Share Growth Rate of Durect was 60.10% per year. The lowest was -55.70% per year. And the median was -8.80% per year.

Back to Basics: PB Ratio


Durect PB Ratio Historical Data

The historical data trend for Durect's PB Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Durect Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
PB Ratio
Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 32.45 10.50 3.88 3.15 1.21

Durect Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
PB Ratio Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 3.15 7.22 22.20 4.93 1.21

Competitive Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, Durect's PB Ratio, along with its competitors' market caps and PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Durect PB Ratio Distribution

For the Drug Manufacturers industry and Healthcare sector, Durect's PB Ratio distribution charts can be found below:

* The bar in red indicates where Durect's PB Ratio falls into.



Durect PB Ratio Calculation

The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. It is a ratio widely used to value stocks.

Durect's PB Ratio for today is calculated as follows:

PB Ratio=Share Price/Book Value per Share (Q: Dec. 2023)
=0.91/0.487
=1.87

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

It can also be calculated from the numbers for the whole company:

A closely related ratio is called Price-to-Tangible-Book. The difference between Price-to-Tangible-Book and PB Ratio is that book value other than intangibles are used in the calculation.


Durect  (NAS:DRRX) PB Ratio Explanation

Unlike valuation ratios relative to the earning power such as PE Ratio, PE Ratio without NRI, PS Ratio, Price-to-Operating-Cash-Flow , or Price-to-Free-Cash-Flow, the PB Ratio measures the valuation of the stock relative to the underlying asset of the company.

The PB Ratio works the best for the businesses that earn most of their profit from their assets, e.g. banks and insurance companies.


Be Aware

Some businesses have very light assets, such as software companies or insurance agencies. The PB Ratio does not work well for these companies. Some companies even have negative equity, so the PB Ratio cannot be applied to them.


Durect PB Ratio Related Terms

Thank you for viewing the detailed overview of Durect's PB Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Durect (Durect) Business Description

Traded in Other Exchanges
Address
10260 Bubb Road, Cupertino, CA, USA, 95014
Durect Corp is a biopharmaceutical company. It is engaged in the research, development, and manufacturing of pharmaceutical products. The company develops pharmaceutical products based on two categories which include new chemical entities and proprietary pharmaceutical programs. The company's pipeline products consist of DUR-928, POSIMIR, and others. Geographically, the company operates in the United States, Europe, Japan, and other countries, of which key revenue is derived from the Europe .
Executives
Judith J. Robertson director 10260 BUBB ROAD, CUPERTINO CA 95014
Gail J Maderis director 364 LOMBARD ST., SAN FRANCISCO CA 94133
Timothy M. Papp officer: Chief Financial Officer C/O DURECT CORPORATION, 10260 BUBB ROAD, CUPERTINO CA 95014
Gail M Farfel director 142 TEMPLE STREET, SUITE 205, NEW HAVEN CT 06510
Mohammad Azab director C/O SUPERGEN, INC., 4140 DUBLIN BLVD., SUITE 200, DUBLIN CA 94568
Peter S Garcia director ALX ONCOLOGY HOLDINGS INC., 866 MALCOLM ROAD, SUITE 100, BURLINGAME CA 94010
Simon X Benito director 967 LAWRENCE AVE, WESTFIELD NJ 07090
Norman Sussman officer: Chief Medical Officer C/O DURECT CORP., 10260 BUBB ROAD, CUPERTINO CA 95014
Bleichroeder Lp 10 percent owner 1345 AVENUE OF THE AMERICAS, 47TH FLOOR, NEW YORK NY 10105
Judy R Joice officer: Sr. VP Operations & Corp QA 10260 BUBB ROAD, CUPERTINO CA 95014
21 April Fund Lp 10 percent owner 1345 AVENUE OF THE AMERICAS, 47TH FLOOR, New York NY 10105
Jon S Saxe director FIRST HORIZON PHARMACEUTICAL CORP, 660 HEMBREE PKWY STE 106, ROSWELL GA 30076
Michael Arenberg officer: Chief Financial Officer 10260 BUBB ROAD, CUPERTINO CA 95014
James E Brown director, officer: President & CEO 10240 BUBB RD, CUPERTINO CA 95014
First Eagle Investment Management, Llc 10 percent owner 1345 AVENUE OF THE AMERICAS, NEW YORK NY 10105